Loading stock data…
TVTX
$48.57+1.49 (+3.16%)
After Hours$48.57+0.00 (+0.00%)· Last close Jun 9
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Travere Therapeutics, Inc. in the Healthcare sector is trading at $48.57. Wall Street consensus targets $55.07 (14 analysts), implying a +13.4% move over the next 12 months. The stock is currently near its 52-week high of $49.21, remaining 49.9% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +13.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$48.57
Potential Downside
0%
Whystock Fair Value$48.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$55.07+13.4%
Range$43.00 – $67.00
Fundamentals
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, o...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.70%
Volume
Today's trading volume
2.21M
Recent News
3 Stocks That May Be Priced Below Their Estimated Value In June 2026
Over the last 7 days, the United States market has dropped 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth prospects.
Extreme Networks And 2 Other Stocks That Could Be Trading Below Their Estimated Value
Over the last 7 days, the United States market has risen by 1.2%, contributing to a significant 27% increase over the past year, with earnings expected to grow by 17% annually. In this thriving environment, identifying stocks that are potentially trading below their estimated value can offer investors opportunities for growth and diversification.
3 Stocks That May Be Priced Below Their Estimated Worth In June 2026
The United States market has shown robust performance recently, climbing 1.2% in the last week and rising an impressive 27% over the past year, with earnings expected to grow by 17% annually. In this environment, identifying stocks that may be priced below their estimated worth can offer potential opportunities for investors seeking value amidst overall market growth.
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside
The licensing deal, announced Tuesday with China’s Everest Medicines, gives Travere exclusive rights to develop and sell the drug civorebrutinib in the United States.
Discover 3 Stocks That May Be Trading Below Their Estimated Value
The United States market has shown robust performance with a 2.5% increase over the last week and a remarkable 26% rise in the past year, while earnings are projected to grow by 17% annually. In this thriving environment, identifying stocks that may be trading below their estimated value can offer compelling opportunities for investors seeking to capitalize on potential growth at attractive prices.